Cryofocus Medtech (Shanghai) Co (HKSE:06922) Net Income From Continuing Operations : HK$-115.66 Mil (TTM As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Cryofocus Medtech (Shanghai) Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cryofocus Medtech (Shanghai) Co's net income from continuing operations for the six months ended in Jun. 2023 was HK$-51.88 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2023 was HK$-115.66 Mil.

Cryofocus Medtech (Shanghai) Co Net Income From Continuing Operations Historical Data

The historical data trend for Cryofocus Medtech (Shanghai) Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cryofocus Medtech (Shanghai) Co Net Income From Continuing Operations Chart

Cryofocus Medtech (Shanghai) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

-188.88

-154.89

-132.13

-115.66

Cryofocus Medtech (Shanghai) Co Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial			-	-52.57	-82.04	-51.88	-63.79

Cryofocus Medtech (Shanghai) Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-115.66 Mil.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cryofocus Medtech (Shanghai) Co Ltd (HKSE:06922) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Building 15, Lane 3399, Kangxin Road, Pudong New Area, Shanghai, CHN, 200120

Website

https://www.cryofocus.com

Cryofocus Medtech (Shanghai) Co Ltd is a medical device company engaged in the research and development, manufacture and sale of cryoablation minimally-invasive interventional treatment technology and related medical products. It has two Core Products, the Bladder Cryoablation System and the Endoscopic Clip for Anastomosis. The Bladder Cryoablation System is a cryotherapy device designed for the treatment of bladder cancer. The Endoscopic Clip for Anastomosis is an anastomotic device for the closure of soft tissue in the digestive tract, which is one of the over-the-scope clips. Geographically company's key revenue is generated from China.

Cryofocus Medtech (Shanghai) Co (HKSE:06922) Headlines

No Headlines